Epinephrine is under clinical development by Nasus Pharma and currently in Phase II for Anaphylaxis. According to GlobalData, Phase II drugs for Anaphylaxis have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Epinephrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epinephrine overview

Epinephrine is under development for the treatment of seasonal allergic rhinitis and anaphylaxis (Severe allergic type 1 reaction). It is administered through nasal spray. It acts by targeting alpha- and beta-adrenergic receptors.

Nasus Pharma overview

Nasus Pharma develops powder-based Intranasal specialized product portfolio, to treat acute medical conditions and public health threats. It offers Powder-Based Intranasal (PBI) specialized product portfolio. Nasus Pharma is headquartered in Tel Aviv, Israel.

For a complete picture of Epinephrine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.